Directed editing of cellular rna via nuclear delivery of crispr/cas9

Kristopher W. Brannan (Inventor), Ryan Marina (Inventor), Eugene Yeo (Inventor), David Nelles (Inventor)

Research output: Patent

Abstract

Disclosed herein is a technology to perform programmable RNA editing at single-nucleotide resolution using RNA-targeting CRISPR/Cas9. This approach, which Applicants have termed “Cas9-directed RNA editing” or “CREDIT,” provides a means to reversibly alter genetic information in a temporal manner, unlike traditional CRISPR/Cas9 driven genomic engineering which relies on permanently altering DNA sequence.
Original languageEnglish (US)
Patent numberUS20230053915A1
Priority date7/11/22
Filing date7/11/22
StatePublished - Feb 23 2023

Fingerprint

Dive into the research topics of 'Directed editing of cellular rna via nuclear delivery of crispr/cas9'. Together they form a unique fingerprint.

Cite this